RMTI Form 144: 6.9K-share insider sale equals 0.02 % of float

Rhea-AI Filing Summary

Rockwell Medical, Inc. (RMTI) filed a Form 144 indicating that 6,926 common shares may be sold under Rule 144. The proposed transaction will be executed through Raymond James & Associates on or after 1 July 2025.

The shares were acquired via RSU vesting on 17 March 2024. At the indicated aggregate market value of $5,536, the filing equates to roughly 0.02 % of the company’s 34.17 million shares outstanding; therefore, the sale is immaterial to share-count dilution and likely has negligible impact on liquidity.

The seller identified in the past-sales table is Mark Strobeck, who disposed of an identical 6,926-share block on 1 April 2025 for gross proceeds of $7,263. The current notice affirms that the filer is not aware of undisclosed material adverse information and is acting in compliance with SEC Rule 144 and related insider-trading provisions.

Overall, the filing represents routine insider portfolio management rather than a signal of fundamental change.

Positive

• Regulatory transparency: Insider is using Form 144, signaling adherence to SEC rules and providing advance notice to the market.
• Minimal dilution risk: 6,926 shares represent only 0.02 % of the 34.17 million shares outstanding.

Negative

• Insider selling signal: Any insider disposal can be interpreted as reduced confidence, although the size here is insignificant.

Insights

Securities Analyst

TL;DR – Minor insider sale (6.9K shares, 0.02 % float); neutral impact on RMTI valuation.

The planned disposition is small in absolute ($5.5K) and relative terms (0.02 % of outstanding shares). The use of Rule 144 and a brokerage intermediary suggests an orderly, compliant process with limited market disruption. No price-sensitive information is revealed, and the seller certifies absence of undisclosed negatives. Given Rockwell Medical’s market cap and float size, I view the filing as non-material for investors and assign a neutral rating.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	6926	5536.00	34174687	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/17/2024	RSU VESTING	ISSUER			21632	03/17/2024	RSU VESTING

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK STROBECK 524 Wyola Farm Ct Newtown Square PA 19073	COMMON	04/01/2025	6926	7263.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Rockwell Medical (RMTI) shares are being sold under Form 144?

The filing covers 6,926 common shares.

What is the market value of the proposed RMTI share sale?

The aggregate market value reported is approximately $5,536.

What percentage of Rockwell Medical’s outstanding shares does the sale represent?

Only about 0.02 % of the 34,174,687 shares outstanding.

When is the expected sale date for the shares?

The filing lists an approximate sale date of 1 July 2025.

How were the shares originally acquired by the insider?

They were obtained through RSU vesting on 17 March 2024.

Which brokerage firm will execute the insider’s sale?

The shares are to be sold through Raymond James & Associates.